MedTrace Logo

Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)

NCT00290563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 557

Last updated 2021-05-19

No results posted yet for this study

Summary

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

Conditions

Interventions

DRUG

MK0594

Sponsors & Collaborators

  • Vyne Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-21
Primary Completion
2007-08-31
Completion
2007-09-24
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00290563 on ClinicalTrials.gov